STK19B

Across TCGA pan-cancer cohorts, STK19B RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of STK19B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where STK19B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types STK19B is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, LIHC, and BRCA are the cancer types where STK19B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STK19B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.732	<.001	8	view →
LIHC	Male	All	+1.145	<.001	7	view →
BRCA	All	II,III,IV	+0.710	<.001	6	view →
KICH	Female	All	−0.877	.001	4	view →
CHOL	All	All	+1.514	.012	2	view →
LUSC	Female	III,IV	+0.570	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

STK19B–KIRC

Open the KIRC breakdown →